This page shows what was measured, who it was measured in, and what that does not settle.
What Toripalimab does in the body
Recurrent unresectable or metastatic NPC with disease progression on or after a platinum-containing chemotherapy ( 1
From the FDA-approved label: Binding of the PD-1 ligands, PD-L1 and PD-L2, to the PD-1 receptor found on T cells, inhibits T cell proliferation and cytokine production. Upregulation of PD-1 ligands occurs in some tumors and signaling through this pathway can contribute to inhibition of active T-cell immune surveillance of tumors. Toripalimab-tpzi is a humanized IgG4 monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response. In syngeneic mouse tumor models, blocking PD-1 activity resulted in decreased tumor growth.
What happened in people
RNAWiki has not yet published a reviewed conclusion for this use.
§ A fixed RNAWiki sentence
Where this came from
Wording RNAWiki always uses, not a finding about this substance.
No reviewed claim names a result for any goal on this record.
No source is stored against this line.
The limit that matters most
Not recorded.
Where it acts
Not recorded.
Kind of result
No result is published, so no kind of result applies yet
Supervision
Professional supervision is normally required. A regulator classifies this substance in a way that restricts how it is supplied.
What the registries record it as
The substance registry classes this as protein.
FDA substance registry · 8JXN261VVA · read 2026-08-29
Where each sentence above came from
No recorded sentence describes the change this makes in a way that stands on its own. The page opens with what it is taken for instead, and the recorded explanation follows below.
Shown as the opening line on this page.
No statement of the main limit is recorded.
The four opening statements run to 126 words.
Words this page uses
Four words worth knowing first
Chosen from what this page shows, with each one explained before the word it depends on.
Biomarker
A biomarker is a number from a test that stands in for something about health.
A picture of it, and where the picture fails
A biomarker is like a fuel gauge.
Where that stops being true. A gauge is wired to the tank. Many biomarkers are only loosely tied to health.
What people get wrong. A better number is read as a better life. Several medicines improved a number and helped nobody.
A measurable indicator used as a substitute for a clinical outcome of interest.
Placebo
A placebo is a dummy treatment given so the real one can be compared with it.
A picture of it, and where the picture fails
A placebo is like a blank control in an experiment.
Where that stops being true. A blank does nothing. People given a placebo often do get better.
What people get wrong. A placebo effect is read as imaginary. The improvement is measured and real.
An inactive intervention matched in appearance to the test intervention, used to control for non-specific effects.
Comparator
A comparator is whatever the treatment was measured against.
A picture of it, and where the picture fails
It is like the other runner in a race.
Where that stops being true. A race has one winner. A study can show both arms improved.
What people get wrong. Results are read without asking what the other group got. Beating nothing is not beating a treatment.
The control condition against which the experimental intervention is assessed.
What happened in people◇Read from sources, not yet reviewed
What happened in people
Each card is one study: the exact question it asked, who was in it, and whether it showed what it set out to show.
3-year Event-Free Survival (EFS) Rate
✗ The study did not show it
Who was studied
NCT07629817
How many people
1044
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
Living longer, or avoiding a major event
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Intravenous
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
FDA label (openFDA SPL) · a recorded source, not a stored snapshot
DFS in the PD-L1-positive population evaluated by the BICR
✗ The study did not show it
Who was studied
NCT05180734
How many people
878
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Intravenous
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
FDA label (openFDA SPL) · a recorded source, not a stored snapshot
ORR
✗ The study did not show it
Who was studied
NCT07309276
How many people
864
Study design
Phase 2
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Intravenous
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
FDA label (openFDA SPL) · a recorded source, not a stored snapshot
Event-free survival
✗ The study did not show it
Who was studied
NCT07154069
How many people
802
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
Living longer, or avoiding a major event
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Intravenous
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
FDA label (openFDA SPL) · a recorded source, not a stored snapshot
3-year events-free survival (EFS) rate
✗ The study did not show it
Who was studied
NCT07554846
How many people
759
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
Living longer, or avoiding a major event
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Intravenous
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
FDA label (openFDA SPL) · a recorded source, not a stored snapshot
Overall survival (OS)
✗ The study did not show it
Who was studied
NCT06095583
How many people
756
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
Living longer, or avoiding a major event
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Intravenous
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
FDA label (openFDA SPL) · a recorded source, not a stored snapshot
What we know
RNAWiki holds 6 written-up human studies for this substance, each with the question it asked.
How we know it
Each card names the study, the number of people and what the study set out to measure.
What this does not prove
These summaries were written by a person and have not been signed off as reviewed claims.
Why it matters
A study that failed is as informative as one that worked, and both are here.
What we still do not know
No reviewed claim exists, so no exact population, effect size or interval is published yet.
What happened in people◇Read from sources, not yet reviewed
How close this is to real life
The top step is something a person would feel or care about. The bottom is a guess from software. Filled steps are where evidence exists for this substance.
■Living longer, or avoiding a major eventEvidence recorded. Death, a heart attack, a stroke, a hospital stay.11 registered measures of this kind. 4 written-up studies measured this and did not show a benefit.
□What a body can do day to dayNo evidence recorded. Walking, dressing, breathing, recovering.No registered study measures this.
□Measured performanceNo evidence recorded. How much was lifted, how far was run, how fast.No registered study measures this.
□Symptoms and quality of lifeNo evidence recorded. Pain, tiredness, mood, sleep, as the person rated it.No registered study measures this.
□A number that stands in for healthNo evidence recorded. Cholesterol, blood sugar, bone density. A stand-in, not the thing itself.No registered study measures this.
■A step measured inside a personEvidence recorded. Something measured in human tissue or human cells.A human record sits on the stored organism ladder.
□AnimalsNo evidence recorded. Mice, rats, dogs. Useful for ideas, not proof about people.No animal record is stored.
■Cells in a dishEvidence recorded. Cells or chemistry on a bench, far from a whole body.Stored mechanism abstracts describe steps measured in cells or tissue.
□A guess from softwareNo evidence recorded. Nobody measured it. RNAWiki never publishes one as a finding.RNAWiki stores no prediction for this record. Software can suggest a link. RNAWiki does not publish one as a finding.
Higher on these steps means closer to something a person would feel. It does not mean better done.
What it would be like to take◇Read from sources, not yet reviewed
Felt, measured, or meaningful
Three different things that get called the same word. Registered studies measured all three, and mixing them is how a blood test becomes a health claim.
Felt
Things a person could notice without a test.
No registered study measured anything of this kind.
Measured
Things only a test, a scale or a device shows.
No registered study measured anything of this kind.
Meaningful
Things that change how a life goes, not only a number.
3 year disease free survival
progression free survival
6 months progression free survival rates
event free survival
1 year progression free survival
overall survival
progression free survival rate at 6 months
complete remission rate
1 year disease free survival
one year progression free survival rate
and 1 more.
A registered study says what someone planned to measure. It does not say what they found. A number moving is not the same as a life going better. The two are shown apart here.
Felt, but not shown to help. A person notices a change. No study showed it leads anywhere good.
Measured, but not felt. A number moves. The person notices nothing. Both can be true.
Measured, but not shown to matter. A number moves in the good direction. Nobody showed that lives went better.
Matters, but takes years. The result that counts may take longer than anyone would keep watching.
Names that fit none of the three (29)
treatment related adverse events as assessed by ctcae v4 0
objective response rates
pathological response rate
dose limiting toxicity
maximum tolerated dose
objective response rate
pathological complete response rates
pcr rate
clinical complete response rate
pathologic complete response rate
experiencing adverse events
progressive disease
partial response
pathological complete response rate
objective tumor response rate
major pathological response rate
complete pathologic response rate
recommended phase 2 dose
disease control rate
pathological complete response
These are harms, study-process measures, or names the rules did not recognise. They are shown rather than dropped.
What it would be like to take◇Read from sources, not yet reviewed
How long anything takes
Nine different lengths of time that get confused with each other. None of them is worked out from another.
Before anything is noticed.RNAWiki does not store this separately, and never works it out from another figure on this page.
Before a test result moves.RNAWiki does not store this separately, and never works it out from another figure on this page.
Before performance moves.RNAWiki does not store this separately, and never works it out from another figure on this page.
How long the result was watched.No finished study window is recorded for a study that tested this substance.
How long people took it.How long people actually took it is not stored. The study window is not the same thing.
How long people were followed.Follow-up length is not stored separately. It is never read off the study window, which would be a different thing.
How fast the body clears it. 10 ± 1.5 days
Read from the label, which states: “The mean terminal half-life (t 1/2 ) (± standard deviation) was 10 ± 1.5 days after the first dose and 18 ± 9.4 days at steady state.”
How long effects linger.RNAWiki does not store this separately, and never works it out from another figure on this page.
Beyond the studies. Nothing is recorded about the long term.
The longest finished study sets the edge of what anyone measured.
A study window is not how long people took it, and neither is how long they were followed. Where RNAWiki holds only one of the three, it shows one.
What is missing or unclear◇Read from sources, not yet reviewed
Were people like you studied?
RNAWiki cannot tell whether a study fits you. It can show who was in it, and where the result stops carrying.
Who was studied
People similar to this profile were included.
LOQTORZI is a programmed death receptor-1 (PD-1)- blocking antibody indicated: in combination with cisplatin and gemcitabine, for first-line treatment of adults with metastatic or with recurrent locally advanced nasopharyngeal carcinoma (NPC) ( 1.1 ) as a single agent for the treatment of adults with recurrent unresectable or metastatic NPC with disease progression on or after a platinum-containing chemotherapy (…
Who is missing from the studies
Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What the label states about particular groups
On pediatric, the label states: “The safety and effectiveness of LOQTORZI have not been established in pediatric patients [see Indications and Usage (1) ].”
US prescribing information · 82e7921a-1e84-4988-9799-0ad7d19b2a75 · read 2026-08-30
On older people, the label states: “Clinical studies of LOQTORZI did not include sufficient numbers of patients aged 65 years and over with NPC to determine whether they respond differently from younger patients.”
US prescribing information · 82e7921a-1e84-4988-9799-0ad7d19b2a75 · read 2026-08-30
On people who are pregnant, the label states: “Risk Summary Based on its mechanism of action, LOQTORZI can cause fetal harm when administered to a pregnant woman [ see Clinical Pharmacology (12.1) ] .”
US prescribing information · 82e7921a-1e84-4988-9799-0ad7d19b2a75 · read 2026-08-30
On people who are breastfeeding, the label states: “Risk Summary There are no data on the presence of toripalimab-tpzi in human milk or its effects on the breastfed child or on milk production.”
US prescribing information · 82e7921a-1e84-4988-9799-0ad7d19b2a75 · read 2026-08-30
Where the result stopped carrying
This is a scope explorer, not a diagnosis engine.
It shows who was studied so you can see whether people similar to you were included.
RNAWiki cannot tell whether a study fits you. It can show who was in it.
What it would be like to take◇Read from sources, not yet reviewed
Why it might seem to do nothing
A real effect and a noticed effect are different things. These are the recorded reasons the two come apart.
It was studied for a different goal
The studies measured something else entirely.
On this record: Some registered studies measured things that match no goal on this page.
It was studied in different people
The people in the studies were not much like the reader.
On this record: Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
The evidence may simply be wrong
Small early studies often do not hold up.
On this record: RNAWiki has not yet published a reviewed conclusion for this use.
Other reasons RNAWiki checked and found nothing for (10)
A different form was studied
The studied form is not the form on the shelf. Nothing in this record points to this reason.
There was nothing to correct
Where a level is already normal, topping it up may change nothing. Nothing in this record points to this reason.
Something else had to happen too
In the studies it was paired with training, a diet or another treatment. Nothing in this record points to this reason.
The change is too small to feel
A real change can still sit below what a person notices. Nothing in this record points to this reason.
Day-to-day swing hides it
Sleep, food, stress and time of day move most numbers more than this would. Nothing in this record points to this reason.
Not enough time yet
The studies ran longer than the person has waited. Nothing in this record points to this reason.
It was not taken as studied
Missed days change the result, and studies count them. Nothing in this record points to this reason.
Something else changed at the same time
Two changes at once cannot be told apart afterwards. Nothing in this record points to this reason.
The product may not be what it says
Contents of a sold product are not always what the label states. Nothing in this record points to this reason.
No recorded reason
RNAWiki has nothing stored that would explain it. Nothing in this record points to this reason.
None of these is a reason to take more. Taking more is not a step this page ever suggests.
What it would be like to take◇Read from sources, not yet reviewed
What taking it involves
The recorded facts about getting hold of it and using it. Nothing here is a suggestion about what you should do.
How it is supplied
Still being tested
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
Read from the recorded approval status.
No source is stored against this line.
Form and route
Intravenous
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The form and route recorded on this substance.
No source is stored against this line.
Who oversees it
Professional supervision is normally required. A regulator classifies this substance in a way that restricts how it is supplied.
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
Suppression classes recorded: S1, S3, S4.
No source is stored against this line.
What is in the pack
Sold as injection, given by the intravenous route.
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
Recorded notes on how this is sold and what that means for what is in the pack.
No source is stored against this line.
Where it is registered
Regulatory records are listed in the technical disclosure at the foot of this page.
# Counted from records
Where this came from
A count of rows RNAWiki holds. It describes our records, not your body.
Register entries are stored per jurisdiction and shown with their dates.
No source is stored against this line.
Why people stop
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
No record of why people stopped taking it is stored for this substance.
No source is stored against this line.
What it would be like to take∅Nothing found in the sources checked
What can go wrong
Sorted by where each line came from. A regulator's label and a report somebody sent in are not the same kind of fact.
∅Nothing found in the sources checked
No harm is recorded against this substance in the sources RNAWiki checked. Finding nothing is not the same as showing there is nothing.
The sources listed were searched and held nothing. That is not the same as nothing existing.
Reports sent to a regulator
These are reports people sent to a regulator. They do not show the medicine caused the reaction.
Nobody counted how many people took the medicine and reported nothing.
The same event can be reported more than once, and many reports are incomplete.
News coverage, lawsuits and new warnings change how often people report.
A count is not a rate and not a risk.
Toripalimab appears in spontaneous reports to regulators. Across the 10 most-reported reaction terms, 10663 reaction mentions were counted. One report can name several reactions.
open-targets-adr · recorded 2026-06-24 · a recorded source, not a stored snapshot
Over a long time. No completed tested study window is recorded, so long-term effects are not established by the registry record.
Groups the studies covered thinly. Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What is missing or unclear◇Read from sources, not yet reviewed
Does the exact form matter?
Evidence belongs to the exact thing that was tested. A different salt, a different mixture or a different preparation is a different question.
The form that was studied
Intravenous
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The form used in the studies cited on this page.
No source is stored against this line.
What is sold
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
Nothing further is recorded about which forms are sold.
No source is stored against this line.
What is recorded as being sold
1 product lists this as an active ingredient in the United States drug directory. 1 of them contain it and nothing else.
FDA National Drug Code directory · 70114-340 · read 2026-08-29
They are sold as injection, taken intravenous.
FDA National Drug Code directory · 70114-340 · read 2026-08-29
The regulator's established pharmacologic class for it is programmed death receptor-1 blocking antibody [epc] and programmed death receptor-1-directed antibody interactions [moa].
FDA National Drug Code directory · 70114-340 · read 2026-08-29
1 published label names it as an active ingredient. 1 of them describe this substance alone, which is where its own label text on this page comes from.
US prescribing information · 82e7921a-1e84-4988-9799-0ad7d19b2a75 · read 2026-08-29
Those labels are classed as human prescription drug.
US prescribing information · 82e7921a-1e84-4988-9799-0ad7d19b2a75 · read 2026-08-29
LOQTORZI is intravenous at 3 DOSAGE FORMS AND STRENGTHS Injection: 240 mg/6 mL (40 mg/mL) clear to slightly opalescent, colorless to slightly yellow solution in a single-dose vial., recorded as fda label in effect 2026-07-23 in the United States.
US prescribing information · 82e7921a-1e84-4988-9799-0ad7d19b2a75 · read 2026-08-30
Evidence carries across two names for one substance. It does not carry across a salt, a mirror form or a mixture.
What it would be like to take◇Read from sources, not yet reviewed
What you could measure
This one is decided with a clinician, so this section holds questions to ask rather than a plan to run.
Self-experiment planning is not offered for a prescription or clinician-supervised medicine. The questions below are for a clinician or pharmacist.
Questions worth asking
Which of the trials of Toripalimab studied people like me?
What was measured, and for how long?
Was the result a laboratory value or a health outcome?
What would we watch for, and when would we stop?
Tracking can show whether something changed for you. It cannot show what caused it.
RNAWiki records evidence. It does not say whether this substance is right for you.
What is missing or unclear◇Read from sources, not yet reviewed
What nobody knows yet
Open questions, each with why it is open and what would close it.
Missing populations
Which groups were under-represented in the studies has not been recorded.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing long-term data
No completed tested study window is recorded.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
No reviewed conclusion
RNAWiki has not yet published a reviewed conclusion for this use.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing interaction studies
No interaction was found in the registers checked. Not finding one is not the same as showing there is none.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Formulation uncertainty
Several salts, forms or products of Toripalimab are recorded. Results from one form may not transfer to another.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Mechanism not reviewed
No reviewed mechanism story exists for this substance.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
What happened in people◇Read from sources, not yet reviewed
Check any of this yourself
Every line above traced back to the study it came from. This is the technical layer, and the vocabulary changes here.
Where else this substance is registered
FDA substance identifier (UNII)
8JXN261VVA
CAS registry number
1924598-82-2
WHO international nonproprietary name list entry
10820
EMA substance identifier
100000183534
DrugBank
DB15043
Checks this page had to pass
✓ Passed
Identity resolved
no open identity hold
✓ Passed
No unresolved merge across substance families
no quarantine open
✓ Passed
Every public sentence names a source
The opening statement carries the origin: Written into the record, not signed off.
✗ Not passed
Trial roles classified for highlighted evidence
No registered study is classified as testing this substance.
✓ Passed
No internal keys in reader text
enforced by the copy-contract test over the rendered page
✓ Passed
Safety mode resolved
Suppression classes recorded: S1, S3, S4.
✓ Passed
Canonical metadata present
slug and display name present
What is missing or unclear◇Read from sources, not yet reviewed
How this medicine reached us
Kept near the foot of the page. A historical event moves up only when it changes something about this substance today.
What the approval register records
The earliest marketing start date recorded for a listed product is 20231027.
FDA National Drug Code directory · 70114-340 · read 2026-08-29
What is missing or unclear◇Read from sources, not yet reviewed
What to learn next
Ordered by what would most change how you read this page, starting with what is easiest to misunderstand.
This order is fixed in code and does not count clicks or time on the page.
What is not here
6 questions this page could not answer
These sections were prepared and left out because there was nothing to put in them. They are listed rather than hidden, so the gaps in this record are visible.
What was measured, goal by goal — found nothing in the sources checked.
The path through the body — found nothing in the sources checked.
What it may clash with — found nothing in the sources checked.
Other ways to the same goal — found nothing in the sources checked.
Claims that go past the evidence — found nothing in the sources checked.
What changed on this page — found nothing in the sources checked.
The record as stored
The full record, for auditing
Everything above is built from what is below. This layer keeps the technical vocabulary, record identifiers and every stored row, so a reader who wants to check the page can.
Recorded evidence blocks (12)
Q2
What did Toripalimab's largest trial (1200 people) and its longest (12 years) measure?
1200 people in Toripalimab's largest registered study, 12 years in its longest registered window, measuring overal survival time(OS). ClinicalTrials.gov · 2026-09-01
270 phase2, 90 phase1, 38 phase3, 11 na or unstated, 10 na, 4 early phase1, 2 phase4; NCT04778956; 2033-03-03; no ageing endpoint recorded. Last human test completed 2026, NCT04354662.
Interpretation These counts include studies where Toripalimab was a comparison treatment, a background treatment or an exposure in an observational study, and the longest window may be a planned end date. Trial roles have not yet been classified for this record.
Show the evidence
phase2
270
phase1
90
phase3
38
na or unstated
11
na
10
early phase1
4
2 more recorded rows
phase4
2
Last recorded human testNCT04354662
2026-07-06
recorded 2026-09-01 · last checked 2026-09-04
Q3
Toripalimab was tested only in human — what did it show?
Interpretation overal survival time(OS) — the recorded outcome words.
Show the evidence
humanNCT06441344
lifespan; overal survival time(OS); 361
recorded 2026-09-01 · last checked 2026-09-04
Q4
17 of Toripalimab's trials stopped: safety, accrual/recruitment, funding/business, other?
safety (3), accrual/recruitment (3), funding/business (1) and other (10): Toripalimab's stop wording, clustered. ClinicalTrials.gov · 2026-09-01
"No patients enrolled."; 17 of 361 registered studies
Show the evidence
Trial
NCT03623776
withdrawn; "No patients enrolled."
NCT03867370
terminated; "Enrollment is over, the study was completed"
NCT03919383
withdrawn; "No participants enrolled"
NCT04084158
suspended; "combination arm delevelped significant poor prognosis"
NCT04284488
terminated; "Company Strategy"
NCT04418648
terminated; "Since the interim results of the ADRIATIC trial presented at the ASCO Annual Meeting in June 2024, the design of the control group is no longer consistent with current clinical practice."
11 further recorded trials
NCT04568304
withdrawn; "This study was not conducted"
NCT04603040
terminated; "Company R\&D Strategy"
NCT04737122
terminated; "Failure to achieve expected outcomes"
NCT04804696
terminated; "Several clinical trials had showed that anti-PD-1 agents combined with chemotherapy as neoadjuvant treatment could increase pCR rate in 2024. In order to protect the interest of patients, this trial was stopted."
NCT05165849
withdrawn; "sponsor decided to withdraw the study"
NCT05253105
withdrawn; "transfer the study to another sponser"
NCT05427396
terminated; "The trial was stopped early on the initiative of the sponsor on the basis of a change in the research and development strategy without safety concerns"
NCT05757492
terminated; "The study was terminated for strategic reasons (not for safety concerns)"
NCT06105008
withdrawn; "Due to the company's strategic adjustment (non-security related)"
NCT06114940
terminated; "Involving changes to the primary endpoint, it is difficult to unify the evaluation criteria for subjects' endpoints before and after the change."
NCT06732258
withdrawn; "Inorder to avoid the serious adverse effect of Toripalimab combining with Tifcemalimab, considering as the protection of participants."
recorded 2026-09-01 · last checked 2026-09-04
Q5
Human studies of Toripalimab used Toripalimab 240mg — over how long?
3 recorded entries; human; IV; also "Toripalimab 240mg", "Toripalimab IV 240mg + platinum-based doublet chemotherapy", "Toripalimab (240mg day1, Q3W*3cycle)"
Show the evidence
human
NCT04389073
Toripalimab 240mg
NCT06437977
IV; Toripalimab IV 240mg + platinum-based doublet chemotherapy
NCT06843889
Toripalimab (240mg day1, Q3W*3cycle)
recorded 2026-09-01 · last checked 2026-09-04
Q6
Toripalimab's half-life is 10 ± 1.5 days — which schedules were studied?
10 ± 1.5 days, the half-life Toripalimab's label states. openfda-label · 82e7921a-1e84-4988-9799-0ad7d19b2a75 · 2026-08-30
Show the evidence
half life
10 ± 1.5 days; The mean terminal half-life (t 1/2 ) (± standard deviation) was 10 ± 1.5 days after the first dose and 18 ± 9.4 days at steady state.
metabolism
Metabolism Toripalimab-tpzi is expected to be metabolized into small peptides by catabolic pathways.
recorded 2026-08-30 · last checked 2026-09-04
Q7
Which of 1 year disease free survival, 1 year progression free survival and 3 year disease free survival did Toripalimab's trials measure?
1 year disease free survival, 1 year progression free survival and 3 year disease free survival lead 40 outcome terms across Toripalimab's trials. ClinicalTrials.gov · 2026-09-01
The rate of pathologic complete response（pCR%）; Objective Response Rates (ORR); latest 2035-03-31
Show the evidence
Trial
NCT03691454
"Compare Neoadjuvant DOS Combined With Toripalimab Versus SOX Combined With Toripalimab in Locally Advanced Gastric Adenocarcinoma"; n 248; "The rate of pathologic complete response（pCR%）"; 2027-06-30
NCT03810339
"Toripalimab（JS001） as Monotherapy in Participants With POLE or POLD-1 Mutated and Non-MSI-H Advanced Solid Tumors"; n 35; "Objective Response Rates (ORR)"; 2029-12-31
NCT03859128
"Toripalimab or Placebo as Adjuvant Therapy in Hepatocellular Carcinoma After Radical Resection"; n 427; "BICR-RFS"; 2027-12-31
NCT03926338
"Neoadjuvant Toripalimab With or Without Celecoxib in dMMR/MSI-H Colorectal Cancer"; n 270; "Pathological complete response (pCR) rates (PICC-1 and PICC-2 cohorts)"; 2030-04-01
NCT04365036
"A Multicenter, Phase 3, Randomized Trial of Sequencial Chemoradiotherapy with or Without Toripalimab (PD-1 Antibody) in Newly Diagnosed Early-Stage Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (ENKTL)"; n 207; "progression free survival (PFS)"; 2028-12-31
NCT04376866
"Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma"; n 204; "Overall survival (OS)"; 2028-04
14 further recorded trials
NCT04387084
"Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy"; n 10; "Percentage of patients completely adhering to 3 cycles of short term fasting (STF) (9 days of fasting)"; 2027-08-12
NCT04517214
"Comparing Chemotherapy With/Without Toripalimab For Primary Metastatic Nasopharyngeal Carcinoma"; n 100; "Progression-free survival"; 2026-12-31
NCT04772287
"Adjuvant Toripalimab Plus Chemotherapy for EGFR/ALK Mutation Negative Stage II-IIIB(N2) NSCLC (LungMate-008)"; n 341; "Disease-free survival (DFS)"; 2027-12-30
NCT04778956
"Toripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal Carcinoma"; n 218; "Disease-free survival"; 2033-03-03
NCT04785196
"APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors"; n 95; "Dose Limiting Toxicity (Phase I)"; 2027-01
NCT04807140
"Neoadjuvant Toripalimab or Toripalimab in Combination With Carboplatin and Nab-paclitaxel in Untreated HNSCC (HNSCC-002)"; n 57; "Percentage of participants demonstrating pathological response"; 2027-01-01
NCT04861584
"Neoadjuvant Toripalimab in Combination with Gemcitabine and Cisplatin Therapy in Local Advanced Bladder Cancer Subjects"; n 41; "Pathological response rate evaluated after 4 cycles of neoadjuvant Toripalimab in combination with gemcitabine and cisplatin at time of radical cystectomy, each cycle is 21 days"; 2027-04-03
NCT04918186
"Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer"; n 60; "To efficiently identify based on objective response rate (ORR), by investigator assessment using RECIST 1.1, promising immunotherapy combinations for the treatment of high grade serous ovarian cancer for later validation in randomized…"; 2026-12-31
NCT05033392
"PD-1 Blockade With JS001 Plus Neoadjuvant Chemotherapy for Gastric/Gastroesophageal Junction Cancer"; n 62; "Pathological complete response rate"; 2027-12-31
NCT05125055
"Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC"; n 80; "Major pathologic response"; 2026-12-30
NCT05147844
"Toripalimab Combined With Radiotherapy in the Treatment of Oligometastatic Nasopharyngeal Carcinoma"; n 40; "1-year progression-free survival rate according to RECIST v1.1"; 2026-03-01
NCT05167071
"HBM4003 Combine With Toripalimab in Patients With Advanced NEN and Other Solid Tumors Study"; n 53; "Part 1: DLT"; 2026-06-30
NCT05302284
"A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma"; n 452; "Progression-free survival (PFS), evaluated by independent review committee"; 2028-04-30
NCT05340491
"Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial"; n 212; "Overall survival"; 2028-12
recorded 2026-09-01 · last checked 2026-09-04
Q9
Which running trial of Toripalimab could settle lifespan?
NCT06323382 measures Progression-Free-Survival (PFS), reading out 2025-12-30.
66 open trials; n 240; "Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma"
Show the evidence
Trial
NCT06323382
"Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma"; n 240; "Progression-Free-Survival (PFS)"; 2025-12-30
NCT06333561
"HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma"; n 300; "Overall survival"; 2025-12-30
NCT05147844
"Toripalimab Combined With Radiotherapy in the Treatment of Oligometastatic Nasopharyngeal Carcinoma"; n 40; "1-year progression-free survival rate according to RECIST v1.1"; 2026-03-01
NCT05888402
"Induction Chemotherapy and Toripalimab Followed by Chemoradiotherapy for Large-volume Local Advanced NSCLC"; n 50; "Progression-free survival (PFS)"; 2026-03-20
NCT07371897
"Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial"; n 154; "2-year Event-Free Survival"; 2026-09-30
NCT06416696
"Toripalimab for High-risk Locally Advanced Cervical Cancer"; n 57; "progression-free survival (PFS)"; 2026-12
14 further recorded trials
NCT06124963
"A Study of WX390 Combined With Toripalimab in Patients With Advanced Gastric-type Endocervical Adenocarcinoma With STK11 Mutations"; n 20; "Progression-free survival rate (PFS rate)"; 2026-12-09
NCT06201065
"FOLFOX-HAIC Plus Lenvatinib and Toripalimab vs. FOLFOX-HAIC Plus Lenvatinib for Advanced Hepatocellular Carcinoma: a Randomized Controlled and Double-blind Trial"; n 200; "Overall Survival (OS)"; 2026-12-26
NCT06354231
"DV Combined With Toripalimab for Renal Preservation in Solitary Kidney or Renal Insufficiency or Bilateral Multiple UTUC"; n 20; "Kidney-intact disease-free survival, KI-DFS"; 2026-12-30
NCT04517214
"Comparing Chemotherapy With/Without Toripalimab For Primary Metastatic Nasopharyngeal Carcinoma"; n 100; "Progression-free survival"; 2026-12-31
NCT06735131
"The Optimal Radioimmunotherapy Combinations for Advanced TNBC"; n 60; "Progression-free survival at 6 months (6m-PFS rate)"; 2027-01
NCT06919848
"Oncolytic Virus H101 Combined With Lenvatinib Plus Toripalimab Compared With FOLFOX in Patients With Advanced Biliary Tract Cancer (OPTIONS-06)"; n 74; "Overall survival (OS) evaluated by the investigator per Response Evaluation Criteria in Solid Tumors Version 1.1"; 2027-05-01
NCT05342194
"Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study"; n 480; "Overall survival (OS) in Arm A compared with Arm C (OS A vs. C)"; 2027-05-31
NCT06851247
"GAPP Induction and Concurrent Chemoradiotherapy Followed by Toripalimab Maintenance for Nasopharyngeal Carcinoma."; n 47; "2-year progression-free survival"; 2027-06
NCT07376499
"Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction"; n 31; "Progression-free survival (PFS) To evaluate the efficacy of anti-tumor"; 2027-06-30
NCT05628922
"Modulation Therapy for Locally Advanced NPC Based on Plasma EBV DNA Level Post-ICT"; n 198; "Progression-free survival"; 2027-07-01
NCT06584435
"A Study of Toripalimab in Adjuvant Therapy After Resection of High-risk Renal Cancer"; n 100; "Disease-Free Survival (DFS) as Assessed by Investigator"; 2027-11-01
NCT04772287
"Adjuvant Toripalimab Plus Chemotherapy for EGFR/ALK Mutation Negative Stage II-IIIB(N2) NSCLC (LungMate-008)"; n 341; "Disease-free survival (DFS)"; 2027-12-30
NCT06717464
"Toripalimab Combined With Capecitabine as Postoperative Adjuvant Therapy for Patients With Resectable Advanced Extrahepatic Biliary Tract Cancer"; n 110; "1-year recurrence-free survival rate"; 2027-12-31
NCT06904573
"Probiotics in Advanced Urothelial Carcinoma"; n 222; "Progression-free Survival (PFS)"; 2028-01-01
Q10
Which 21 trials of Toripalimab posted no result?
Posted no result
21 of 21 completed trials
Registrations
NCT03301688, NCT03316144, NCT04044313, NCT04481009, NCT04005170 and NCT04357756, and 15 more
Completion dates
oldest 2019-12-15; newest 2024-08-19
Show the evidence
Trial
NCT03301688
2019-12-15
NCT03316144
2019-12-30
NCT04044313
2022-02-28
NCT04481009
2022-05-26
NCT04005170
2022-07-31
NCT04357756
2022-10-19
14 further recorded trials
NCT05809336
2022-10-31
NCT04169672
2023-02-28
NCT04118855
2023-03-31
NCT04627012
2023-07-01
NCT04144608
2023-07-30
NCT05031494
2023-08-16
NCT04473716
2023-09-30
NCT05188664
2023-11-14
NCT04238169
2023-12-31
NCT04914286
2023-12-31
NCT05386888
2023-12-31
NCT03874897
2024-01-26
NCT04991506
2024-05-17
NCT05102006
2024-05-22
Q11
At the median, Toripalimab's trials enrolled 57 people — anything larger?
Median enrolment
57
Largest enrolment
1200
Registered trials counted
361
Q12
What do 10663 spontaneous reports say about Toripalimab — and not say?
These are reports people sent to a regulator. They do not show the medicine caused the reaction. Nobody counted how many people took the medicine and reported nothing. The same event can be reported more than once, and many reports are incomplete. News coverage, lawsuits and new warnings change how often people report. A count is not a rate and not a risk.
Toripalimab appears in spontaneous reports to regulators. Across the 10 most-reported reaction terms, 10663 reaction mentions were counted: malignant neoplasm progression 3087; colitis 1502; pneumonitis 1465; hypothyroidism 1115. open-targets-adr · CHEMBL4297843 · 2026-06-24
Show the evidence
malignant neoplasm progression
3087
colitis
1502
pneumonitis
1465
hypothyroidism
1115
adrenal insufficiency
730
hepatitis
629
4 more recorded rows
hyperthyroidism
589
hypophysitis
568
tubulointerstitial nephritis
492
myocarditis
486
recorded 2026-06-24 · last checked 2026-09-04
Q13
What is recorded about Toripalimab and mTOR?
"Based on the clinical condition and the patient preference, she was administered a novel combinatorial therapy comprising mTOR inhibitor everolimus, which is a well-known and potent inhibitor of the PI3K/AKT signaling pathway, and the anti-PD-1 antibody toripalimab." — where Toripalimab and mTOR appear together. Europe PMC · pathway abstract search · 2021-12-09
mTOR; PMID 34916808
Show the evidence
mTORPMID 34916808
"Based on the clinical condition and the patient preference, she was administered a novel combinatorial therapy comprising mTOR inhibitor everolimus, which is a well-known and potent inhibitor of the PI3K/AKT signaling pathway, and the anti-PD-1 antibody toripalimab."
recorded 2021-12-09 · last checked 2026-09-04
Where it is registeredIdentifiers, relations and other names
ChEMBL ATC CC BY-SA · ClinicalTrials.gov — US Government work · Europe PMC — metadata only, under the recorded legal gate · Open Targets 26.06 — CC0 · derived from this page's own recorded fields; no external licence · mixed register set; per-register licences in docs/specs/corpus-20k-sources.md · openFDA / DailyMed — US Government work
✗ required summary fields resolved: 5 required field(s) not terminal: Why people use it, Best-supported result, Most important common problem, Biggest unanswered question, Human evidence
✓ public claims reviewed: 0 reviewed claim(s); drafts are never rendered
✓ source coverage passed: 8 source rows
✓ no critical contamination: no quarantine open
✓ canonical metadata passed: slug and display name present
✓ no raw internal fields: enforced by the copy-contract test over the rendered page
This is a record of evidence. It is not medical advice, and it does not say this substance suits you. Nothing here says any substance on RNAWiki is appropriate for a child.